![]() |
市場調查報告書
商品編碼
1245505
甲癬全球市場規模、份額、行業趨勢分析報告,按類型(遠端甲下、近端甲下、白色表面、其他)、治療方法(局部、口服、其他)、區域前景預測,2022-2028 年Global Onychomycosis Market Size, Share & Industry Trends Analysis Report By Type (Distal Subungual, Proximal Subungual, White Superficial and Others), By Treatment (Topical, Oral and Others), By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,甲真菌病的全球市場規模預計將達到 45 億美元,預測期內復合年增長率為 4.8%。
近端甲下甲真菌病 (PSO) 的致病菌首先侵入近端甲板的下側,然後向遠端擴散。 內生甲癬(EO)也指沒有甲床感染的真菌侵入甲板。 完全營養不良性甲真菌病 (TDO) 可能會出現其他亞型,並且是甲真菌病的最後階段。 繼發性甲真菌病(SO),臨床上類似於非真菌性和真菌性甲病,繼發於非真菌性甲病(即牛皮癬)的複雜真菌感染。
COVID-19 影響分析
隨著越來越多的醫院和初級保健診所轉向 COVID-19 患者,大流行減少了診斷數量並影響了藥物和其他甲真菌病治療的銷售。我是。 COVID-19 還影響了人們的免疫力,使他們更容易感染甲癬等真菌病。 它還使已經感染的人復發的風險增加了一倍。 因此,大流行對甲癬市場產生了負面影響。
市場增長因素
管道中潛在候選藥物的研發不斷增加
甲癬的患病率不斷上升,而且缺乏有效的治療方法,這推動了對更好的藥物療法的需求。 許多非處方局部藥物不能深入指甲板,因此無法完全治愈感染。 因此,許多公司都在努力尋找能夠深入指甲的化合物來克服這一挑戰。 許多公司正在積極致力於開發新療法,包括 BB2603 (Blueberry Therapeutics)、Hallux Terbinafine Subungual Gel 和 MOB-015 (Moberg Pharma)。
皮膚癬菌甲癬的患病率上升
甲癬發病率的增加是市場擴張的主要驅動力之一。 甲癬比指甲甲癬更常見。 由皮膚癬菌引起的甲癬患病率上升和處方的顯著增加正在推動對甲癬藥物的需求。 甲癬影響世界上很大一部分人口並折磨數百萬人。 導致甲癬增加的另一個因素是糖尿病發病率的上升。 因此,在未來幾年,所有這些因素都將推動甲癬治療的需求,從而使市場受益。
市場製約因素
低需求彈性和非危及生命的條件
此外,由於皮膚癬菌性甲癬不會危及生命且治療效果低,因此來自無效替代療法的競爭越來越激烈。 例如,茶樹油是一種越來越多地用於治療指甲感染的替代品。 由於潛在的顯著副作用,目前被批准作為甲癬治療選擇的藥物需要進行肝臟篩查和監測。 因此,對治療藥物的需求下降可能會阻礙市場擴張。
按類型劃分的前景
按類型,甲真菌病市場分為遠端甲下、白色淺表、近端甲下等。 到 2021 年,遠端甲下部分將在甲癬市場中佔據最高的收入份額。 由於需求增加和仿製藥滲透率上升,該領域的主導地位與 FDA 批准更多仿製藥有關。 此外,更多藥物正在研發中,以滿足對有效藥物日益增長的需求。 最常見的甲癬類型是遠端甲下。 在這種情況下,甲真菌病區的近端邊緣變得參差不齊,黃白色的尖刺突出到甲板上。
治療前景
根據治療方法,甲癬市場分為口服、外用和其他。 2021 年,口服藥物在甲癬市場的收入份額最大。 該細分市場正在增長,因為與其他形式的抗真菌藥物相比,口服藥物不僅具有更高的治療治愈率,而且治療持續時間更短。 例如,口服鹽酸特比□芬是治療甲癬最常用的藥物。 此外,一些仿製藥製造商正在推出口服藥物來對抗不斷上升的甲癬發病率。 例如,茶鹼緩釋 (ER) 片於 2021 年 6 月獲得美國 FDA 批准。
區域展望
按地區分析了北美、歐洲、亞太地區和 LAMEA 的甲癬市場。 2021 年,北美市場在甲癬市場的收入份額最大。 該地區甲真菌病發病率的增加和有益的政府政策可能是增長的因素。 在發達國家中,北美是人均醫療保健費用最高的國家之一。 此外,北美有很多人患有甲癬。 不斷上升的發病率增加了對有效治療甲真菌病以對抗甲真菌病的需求。 正因為如此,美國公司正在斥巨資開發這些藥物。
The Global Onychomycosis Market size is expected to reach $4.5 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.
A fungal infection of nails called onychomycosis results in thickening and discoloration of the nail plate. In general, the word onychomycosis covers infections caused by yeasts, saprophytic molds, and dermatophytes in addition to dermatophytes. Though fingernails, as well as toenails, can get infected, toenail onychomycosis is more common. Recent studies have shown that mixed infections and infections brought on by non-dermatophyte molds (NDMs) are more common, particularly in warmer climates.
The dermatophyte-induced onychomycosis condition is known as tinea unguium. Subtypes of onychomycosis are categorized according to the invasion pattern. The most prevalent form of onychomycosis, known as distal subungual onychomycosis (DSO), happens when the fungus colonizes the distal portion of the nail plate. Fungi infiltrate the nail plate's outermost layers in superficial white onychomycosis (SWO).
The organism that causes proximal subungual onychomycosis (PSO) first invades from the underside of the proximal nail fold, then the infection subsequently spreads distally. Additionally, Endonyx onychomycosis (EO) refers to the nail plate's fungal invasion that does not involve nail bed infection. Total dystrophic onychomycosis (TDO), which may follow any other subtypes, is the final stage of onychomycosis. Clinically resembling both the non-fungal and fungal nail disorders, secondary onychomycosis (SO) refers to the non-fungal nail condition (that is, psoriasis) along with a secondary fungal infection.
COVID-19 Impact Analysis
As many hospital institutions and primary care clinics switched their attention to COVID-19 patients, the pandemic led to a decline in diagnoses and had an impact on the sales of medications and other onychomycosis treatment options. In addition, COVID-19 also affected the immunity of people, which increased the chances for acquiring fungal diseases like onychomycosis. The risk of recurrence also multiplied for people who already had the infection. Therefore, the pandemic had an adverse impact on the onychomycosis market.
Market Growth Factors
Rising research and development of potential candidates in the pipeline
The rising prevalence of onychomycosis coupled with a lack of viable treatments have increased the demand for better medication. Many of the topical medications on the market cannot reach the depths of the nail bed, making it impossible to entirely heal the infection. As a result, many businesses are trying hard to find compounds that penetrate the nails deeper to overcome this difficulty. Numerous businesses are actively developing new treatments, including BB2603 (Blueberry Therapeutics), Hallux Terbinafine Subungual Gel, and MOB-015 (Moberg Pharma).
Growing prevalence of dermatophytic onychomycosis
Onychomycosis' increasing incidence is one of the major factors propelling the market's expansion. Infection of the toenail onychomycosis is far more common than that of the fingernails. The rising prevalence of dermatophyte-caused nail fungal infections and a large rise in the number of prescriptions are propelling the demand for onychomycosis treatment. A significant number of the world's population has onychomycosis, with millions suffering from nail fungus. A further factor contributing to the rise in dermatophytic infection is the rising incidence of diabetes. Hence, in the coming years, all these factors will expedite the need for onychomycosis treatment, which would benefit the market.
Market Restraining Factors
Low demand elasticity and non-life-threatening condition
The non-life-threatening characteristics of dermatophytic onychomycosis and the treatment's poor efficacy have also led to intense competition from ineffective alternative treatment methods. For instance, tea tree oil is a substitute product that is increasingly utilized to treat nail infections. Since the current medications licensed for the treatment option of onychomycosis have the potential for significant side effects, liver screening and monitoring are necessary. Therefore, the lower demand for the treatment have the potential to hamper the expansion of the market.
Type Outlook
Based on type, the onychomycosis market is categorized into distal subungual, white superficial, proximal subungual, and others. The distal subungual segment garnered the highest revenue share in the onychomycosis market in 2021. The segment's dominance is linked to the FDA's clearance of more generic drugs due to rising demand and rising generic prevalence. Additionally, there are more pharmaceuticals in the pipeline to address the increased demand for effective medications. The most typical kind of onychomycosis is distal subungual. In this, the onycholytic area's proximal edge is ragged, and yellow-white spikes protrude into the nail plate.
Treatment Outlook
On the basis of treatment, the onychomycosis market is divided into oral, topical, and others. The oral segment recorded a significant revenue share in the onychomycosis market in 2021. The segment is growing since oral medications have greater treatment cure rates as well as shorter treatment periods than other forms of antifungals. For example, terbinafine hydrochloride oral medication is the most used treatment for onychomycosis. Additionally, to combat the rising incidence of onychomycosis, some generic drug makers are introducing oral medicines. Theophylline extended-release (ER) tablets, for example, were approved by the U.S. FDA in June 2021.
Regional Outlook
Based on region, the onychomycosis market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment witnessed the maximum revenue share in the onychomycosis market in 2021. Onychomycosis's increased frequency in the region as well as helpful government policies can be attributed to the growth. Among the developed nations, North America has one of the highest per capita healthcare costs. Additionally, many people in North America have onychomycosis. The rising incidence rate is increasing the need for effective onychomycosis treatments in the fight against the disease. Due to this, American businesses have made large expenditures in the creation of these medications.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Market Segments covered in the Report:
By Type
By Treatment
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures